332777
Meaningful Data and Public Health Policy
Purpose: Present different ways of making cancer data meaningful, interesting and accessible to stakeholders. Review and compare how public health data can be presented in useful ways to inspire health in all policies.
METHODS: We reviewed existing public health policies for CCRs. We also reviewed different ways CCRs, national organizations and researchers presented data. We examined how data representations matched with stakeholder’s specific interests. The presentation will demonstrate a variety of data representations.
Results: We will show key components needed to display disease registry data in a way that is meaningful to various stakeholders. There is a need for coordinated efforts to drive towards useful and efficient use of data and best practices to reach the healthy 2020 goals. Awareness of disease registry data are needed to encourage the effective use of cancer data to stimulate change and health for all.
Disdussion/Conclusions: Data to support stakeholders is available but may not be in a meaningful format. By using tools such as dashboards and score cards, we have the ability to make data available in a meaningful way. Coordinated efforts and effective presentation of data will facilitate attainment of Healthy 2020 goals.
Learning Areas:
Communication and informaticsPublic health or related laws, regulations, standards, or guidelines
Public health or related public policy
Public health or related research
Learning Objectives:
Discuss important advocacy and policy for cancer registries and cancer data representation
Keyword(s): Cancer, Information Technology
Qualified on the content I am responsible for because: I am Assistant Research Professor at the University of Missouri School of Medicine/ Department of Health Management and Informatics. Public health research and public health data and databases are in my field of interest and expertise.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.